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Abstract 
In this study we focus on the incorporation of an emerging class of non-toxic and 
photoluminescent materials, namely carbogenic nanoparticles or C-dots, to Pluronic® 
hydrogels. The role of C-dots in those systems is dual; first C-dots can impart significant 
photoluminescent properties absolutely desirable for bioimaging purposes. Second, C-dots are 
expected to be able to offer a further degree of control on the drug release profile of the system. 
The C-dots were synthesised from citric acid monohydrate and ethanolamine using a pyrolysis 
method at 300°C and were functionalised with JEFFAMINES® D-230 and D-400. This study shows 
that C-dots encapsulated in hydrogels exhibit high levels of fluorescence in analogy with the 
well-established behaviour of the dilute aqueous dispersions. The release profiles of ibuprofen 
from the Pluronic® gel suggest that incorporation of C-dots significantly modifies the diffusion 
kinetics in a manner that depends upon the surface functionalities of the nanoparticles. Release 
profiles of paracetamol from the Pluronic® gel were also observed, and compared with that of 
ibuprofen. The faster kinetics observed for C-dot containing hydrogels indicate that addition of 
nanoparticles effectively releases the close packing constrains of the gel. 
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1. Introduction 
1.1 Carbogenic Nanoparticles as Photoluminescent Materials 
Fluorescent materials are currently in enormous demand for many areas and disciplines, due to 
their ability to be used in chemical sensing, drug delivery and bioimaging just to name a few1-3. 
The main obstacles for the development of current chemical sensors are the complex process 
of operation and low levels of sensitivity. These requirements can be easily fulfilled with 
techniques that involve fluorescent materials, making fluorescent based sensors a candidate 
with the most potential for chemical sensing4. A potential use for these chemical sensors is to 
detect explosives and hazardous chemicals, and with recent acts of terrorism, this prospect will 
be in the spotlight5, 6. In 2004, a new prodigy of sensors had been discovered in the form of 
carbogenic nanoparticles, alternatively known as carbon dots (C-dots) and recognised as a new 
category of nano-emitters that are photoluminescent. They have become the primary focus 
with regards to fluorescence imaging due to being tuneable and already having desirable 
characteristics7.  
 
Currently, the amount of medicines involving nanotechnology is climbing, set to spread 
exponentially8.  These C-dots are investigated extensively in a vast range of technological 
applications, with the interest in the C-dots being because of their fluorescent properties, 
economic tuneability, versatility and preparation1-3. In addition, the clear advantages of these 
C-dots in various uses with regards to their outstanding characteristics involve a high cell 
permeability, photostability, chemical stability, great water dispensability, low toxicity, 
multicolour emission based on excitation wavelength, and modifiable easily9. The surface of the 
C-dots are also easy to functionalise and as a result can be synthesised to have high solubility in 
formulations that are water based10. Scientists must consider the brightness and photostability 
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of these luminescent quasi-spherical nanoparticles, especially with them being highly resistant 
to photobleaching – resulting in a high quantum yield9.  
 
A study lead by Wen Sun et al. discovered that the fluorescence of the C-dots was stable when 
exposed to variations in environmental conditions such as UV irradiation, pH and temperature. 
These C-Dots were also observed to be highly selective and sensitive towards ferric ions11.  
 
The ability to disperse and emission intensity of the C-dots is affected significantly depending 
on the environment the C-dots are exposed to. A carbogenic core in combination with surface 
groups is what causes the characteristic fluorescent properties of C-dots. These C-dots have an 
increased resistance against photobleaching, a very low toxicity and minimal invasiveness, 
which gives them dramatic advantages over quantum dots and polyaromatic dyes. The structure 
of the carbogenic core can vary from highly graphitic to completely amorphous, depending on 
the starting materials and the synthetic method used1-3. The fluorescent nature of the C-dots 
allows the interactions involving these nanoparticles to be visualized, and shows fluid 
longitudinal tracking at an individual cell level, at target organs/tissues and of the whole 
animal12.  
 
1.1.1 Formation Mechanism and Properties of Carbogenic Nanoparticles 
Usually, carbogenic nanoparticles can by synthesised in two ways, these methods are known as 
the bottom- up pathway and the top-down pathway. C-dots are synthesised via the bottom-up 
pathway from raw materials using hydrothermal, oxidation, supported synthesis, microwave, 
ultrasonic and combustion methods9. However, the C-dots formed via the top-down pathway 
are synthesised through the breaking down of bulk materials, using methods such as arc 
discharge, plasma treatment, laser ablation and electrochemical exfoliation9.  
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More specifically, the formation mechanism of these C-dots was observed and studied via the 
pyrolysis of ethanolamine (EA)-citric acid (CA) precursor at varying temperatures. The results 
show that the fluorescence levels of the C-dots directly correlate to the conditions that they 
were synthesised in. At high pyrolysis temperatures, the carbogenic core starts to form, but at 
low temperatures the molecular fluorophores are dominant. The fluorescence becomes solely 
responsible from the carbogenic cores at very high temperatures, exclusively from the cores at 
400° and mostly at 300°C. At lower temperatures (approx. 230°C), the carbogenic core has only 
just started to form and the fluorescence emission levels are shared with the molecular 
fluorophores. At 180°C, a high quantum yield via the dehydration of EA-CA can be seen, and the 
pyrolysis at this temperature resulted in a C-dot molecular precursor with a very intense 
fluorescence, but without any fluorescence from the carbogenic cores because they had not 
formed at this temperature8.    
 
The C-dots are made up of amorphous nanocrystalline cores with turbostratic carbon shells that 
can be graphitic or amorphous9, 13, 14. They are mainly synthesised of oxygen, hydrogen and 
carbon atoms with varying ratios between different types of C-dots. The have been 
investigations involving heteroatoms, attempting to create freedom for extra functions and 
change the position band of the C-dots conduction to modify the HUMO-LOMO gap. Involving 
nitrogen could dramatically improve the quantum yield, meanwhile involving sulphur with the 
C-dots resulted in a wide band gap15-23. Furthermore, a surface passivation method devised by 
Sun’s group was utilized to result in an improvement of the quantum yield of C-dots. The most 
fluorescent C-dots showed a quantum yield of 60%, as a result of modifying the non-fluorescent 
C-dots with diamine-terminated poly(ethylene glycol) (PEG1500N). Separation was done using 
an aqueous gel column24.  
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1.1.2 Fluorescence Mechanism of Carbogenic Nanoparticles 
Typically, fluorescence can be described as the absorption of electromagnetic radiation, usually 
light, and then the emission of light that is generally of a longer wavelength, which therefore 
has a lower energy level than that the light being absorbed. However, the behaviour that 
fascinates most scientists comes when fluorescence materials are exposed to light in the UV 
region of the spectrum. When a fluorescent substance absorbs UV light, which is invisible to the 
human eye, it emits visible light in an array of colours. This light emission then immediately 
dissipates upon the removal of the UV light source.   
 
However, the mechanism that causes the fluorescence these C-dots is under speculation 
according to researchers. Since there is such a wide variety of C-dots, different mechanisms 
must be explored using various types of nanoparticles12, illustrated below (Fig. 1.1).   
 
 
 
 
 
 
 
 
 
 
First, graphene-quantum dots (GQDs) have been used as an example of a fluorescent 
nanoparticle and used to derive a potential overall mechanism. It is thought that the 
fluorescence in these GQDs could be caused by several things. Reasons for their fluorescence 
can be due to: (1) defects and surfaces states25, (2) surface passivation26, (3) surface groups27, 
Fig. 1.1. The various structures of C-dots that were used 
in the attempt to devise a fluorescence mechanism12.  
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(4) different sized nanoparticles optical selection28, (5) fluorophores with different degrees of π 
conjugation29, 30, or (6) the radiative recombination in pairs of electron-holes in sp2 clusters31.  
 
Second, experiments carried out by Kang et al. involving carbon nanodots (CNDs) showed that 
fluorescence properties were affected by the size of the nanoparticles. Emission wavelengths 
started at UV and changed through to infrared when the CNDs were small through to relatively 
large respectively.  Further investigation showed that the strong emission levels coming from 
the C-dots is due to their quantum-sized graphite structure12.  
 
A mechanism known as the crosslink-enhanced emission effect (CEE) has been discovered using 
polymer dots (PDs). The potentially fluorescent centres of these PDs have their fluorescent 
properties amplified by the CEE effect. This is believed to be due to the decrease in rotation and 
vibration of the crosslinked PDs12.  
 
A mechanism suggested by Sun et al. describes that the fluorescence of the C-dots is caused by 
surface energy traps that are present and become emissive after surface passivation26. It was 
theorised that the emissive energy traps experienced quantum confinement to the surface of 
the particles to allow the particle to have intense fluorescence properties after being surface 
passivated26.  
 
1.1.3 Bioimaging with Carbogenic Nanoparticles 
Research into C-dots is increasing, improving the imaging, diagnosis and treatment of various 
diseases as a result. Concerning this, materials at a nanometre scale must be synthesised and 
modified. With the use of these nanoparticles in drug delivery systems within the field of cancer 
medicine, results have shown an improvement in bioavailability, solubility, therapeutic 
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effectiveness, in vivo stability, intestinal absorption and the continual and targeted ability of 
many anticancer agents32.   
 
C-dots have vast potential in the field of fluorescent bioimaging due to their great 
biocompatibility and low toxicity33. Research into how feasible C-dots were in mice as a 
fluorescence contrast led by Yang et al.34. This was done via subcutaneous injections of C-dots 
mixed into aqueous solution. Fluorescence images were then taken at different excitation 
wavelengths, with the green and red emissions contrasting sufficiently for imaging35. This same 
experiment has been repeated by Tao et al. giving similar results. The fluorescence imaging that 
followed was at seven excitation wavelengths between 455nm and 704nm (shown in Fig. 1.2). 
The best fluorescence contrast appeared at the 595nm excitation wavelength36. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2. In vivo fluorescence images upon the injection 
of C-dots subcutaneously into live mice, with various 
wavelength excitations. In addition, the fluorescence 
intensities at different excitation wavelengths are 
shown in a graph32. 
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The C-dots become highly fluorescent due to being surface-passivated by organic or 
biomolecules, and have now been found to be photo-chemically stable, physio-chemically 
stable and non-blinking37.  The fluorescence of the carbon core within these C-dots can also be 
further improved via doping before the surface functionalization using an inorganic salt such as 
ZnS38. In addition, it has been shown by Wang et al. that the fluorescence properties of C-dots 
can also be enhanced via doping with nitrogen to result in structure effects39.  
 
1.1.4 Toxicity of Carbogenic Nanoparticles 
Experiments on the cytotoxicity of carbogenic nanoparticles were investigated by Tao et al. This 
was done by exposing the human kidney embryonic 293T cell line to three varying types of C-
dots to observe any in vitro toxicity effects. The varying C-dots were organised into different 
concentrations for each type of C-dot, they were then left to incubate for 24h in cells that were 
cultured in 96 well-plates. The cell viabilities were then tested after receiving the treatment of 
C-dots. It was shown that even at extremely high concentrations of C-dots (<0.5 mg/mL) the cell 
viability was not significantly affected. These results show that there are no obvious in vitro 
toxicity effects caused by C-dots (Fig. 1.3)40.  
 
 
 
 
 
 
 
The potential for the use of C-dots for in vivo and in vitro imaging applications is continually 
researched. Although, the toxic effects and toxicity levels of various C-dots have been studied, 
such as LD50 (median lethal dose). It has been proposed that C-dots have a biocompatibility that 
Fig. 1.3. Cell viabilities after exposure to various 
concentrations of three types of C-dots40. 
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is comparable to dyes used in optical imaging agents that have been recently FDA approved. An 
example of these dyes is indocyanine green (LD50 = 60 mg/kg bodyweight) 34.  
 
1.1.5 Carbogenic Nanoparticles for Drug Delivery 
There have been many examples recently showing that C-dots are very versatile and can be used 
in a vast array of areas with regards to drug delivery. The versatility of these particles can be 
seen in their ability to carry so many different types of drugs, with many scientists focusing on 
anticancer drugs as the ultimate objective. Examples of these anticancer drug carrying abilities 
can be seen below: 
 
A study led by Zeng et al. showed fluorescent spherical C-dots with sizes ranging between 2 and 
6 nm, that were green-emitting and had surfaces that were rich with carboxyl groups proved to 
be a working trackable delivery agent for cancer treatment that is localized in a mouse model. 
The normal cells and cancer cells had differing pH levels that could be used as the activating 
mechanism for the release of the drug Doxorubicin (DOX), which was conjugated via non-
covalent bonding to the C-dots with the use of the amine moiety on the drug and the carboxyl 
groups on the C-dots. Even in biological systems that were complex, this stimuli-responsive non-
covalent bonding proved to be adequately stable41. 
 
Similarly, a study led by Feng et al. involving the use of fluorescent C-dots that had dispersion 
that was uniform with particle diameters ranging between 5 and 8 nm. These C-dots were used 
as drug nanocarriers that are imaging-guided, with an active targeting ligand known as RGD 
peptide, covered by monomethoxypolyethylene glycol (mPEG) via pH responsive benzoic-imine 
bond and cisplatin (IV) as the prodrug carried by the C-dots. Together, they form a pH/redox 
dual responsive type of C-dots that significantly enhance anticancer drug delivery and have 
targeting abilities that are triggered via tumour extracellular microenvironments42. 
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Furthermore, a study led by Karthik et al. describes the conjunction of a quinoline based photo-
trigger with fluorescent C-dots to give a nano drug delivery system that is photo-responsive. The 
C-dots used had a particle diameter ranging between 5 and 7 nm, before being conjugated with 
an anticancer drug that could be photo-triggered known as 7-(3-bromopropoxy)-2-
quinolylmethyl chlorambucil (Qucbl). Efficient anticancer drug release was observed through 
the exploitation of the photo-trigger ability of quinoline, with the use of both one-photon and 
two-photon excitation methods43. 
 
1.2 Polymeric Prodrugs as a Model Drug Delivery System 
Polymeric prodrugs can be described as inactive pharmaceutical agents that may transform 
enzymatically or chemically, forming an active parent drug within an organism after 
administration44. Some prodrugs remain inactive until they arrive at the desired site of action45. 
These drugs tend to be only one to two enzymatic/chemical steps away from the desired active 
parent drug, and as a result, they tend to be closely similar derivatives of the desired drug. In 
these materials, the drug release can be initiated by the cleavage of a chemical bond in drug 
delivery systems of a specific type44. Developments have been observed in the properties of 
pharmacologically active compounds via prodrug application. These properties include types 
such as physiochemical, pharmacokinetical and biopharmaceutical. It has been established at 
an estimate that approximately 10% of worldwide marketed drugs can be labelled as prodrugs, 
with a third of all approved small molecular drugs becoming known as prodrugs in 200844. 
 
The concept of polymeric prodrugs involves the use of designed novel agents, the aim of which 
is to accomplish selective activity at a specified target site, applying activation enzymatically that 
is specific to that site of action46. However, not all types of prodrugs have a carrier that is 
immediately obvious, thus revealing the requirement for molecular modification to generate a 
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new active compound. Various prodrugs specifically designed to overcome toxicity, formulation 
and delivery barriers to the application of drugs have reached the drug market47.  
 
The desired goal of a prodrug is to conceal unwanted properties in the drug, this properties 
include: chemical instability, low solubility in water/lipid membranes, pre-systematic 
metabolism, toxicity, undesired taste, minimal target selectivity and local administration 
resulting in soreness or irritation48.  There are three overlapping objectives to strive towards 
with regards to the research of prodrugs: 
 
The first objective being pharmaceutical; improving the solubility of the drug, along with its 
chemical stability, organoleptic properties, to decrease problems that could be linked to the 
pharmaceutical technology of the active agent, and to diminish irritation and/or pain upon the 
administration of the drug49. 
 
The second objective being pharmacokinetical; improving the amount of time the drug remains 
within a patients’ body before degrading fully, along with the absorption of the drug, and to 
improve the tissue/organ-selective distribution of the active agent49. 
 
The third objective being pharmacodynamical; reducing toxicity levels of the drug, advancing its 
therapeutic index as a result, and to form single chemical units containing multiple drugs49. 
 
1.2.1 Structure of Polymeric Prodrugs 
The synthesis of macromolecular prodrugs can be done by taking molecular drugs that are small 
and conjugating them covalently alongside polymeric carriers. It has been proven that these 
prodrugs result in a controlled and sustained release of a desired therapeutic agent in vitro/in 
vivo. Polyethylene glycol (PEG) is a good example of a prodrug that is macromolecular and has 
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been extensively used due to its low toxicity, high biocompatibility and low immunogenicity. 
However, PEG that is linear has a constant number of available hydroxyl groups through 
polymeric chain length changes. As a result, this means the PEG has limited application in 
purposes involving drug conjugation50.  
In the Ringsdorf model of a polymeric prodrug there are five main components that make up 
the drug: the polymeric backbone, the solubilising group, the targeting group, the 
biodegradable spacer and the drug, as shown below (Fig. 1.4). 
 
First, for the polymeric backbone to become a viable option in the prodrug due to its 
responsibility for drug delivery, certain criteria must be met. The functional groups in the 
polymer must be suitable in that they must be available for covalent coupling with drugs such 
as; -NH2, -SH, -COOH, or –OH. The polymer must have a good water solubility, aka hydrophilic. 
The polymer should be readily available so that it can be manufactured at a sufficient capacity 
and must be properly administered to patients in need of the drug. The polymer must also be 
non-toxic, non-immunogenic, non-antigenic, biocompatible, and biodegradable and must have 
a molecular weight below the renal excretion limit. Finally, the final conjugates of the polymer 
must have an acceptable homogeneity, aka a low polydispersity51.  
Fig. 1.4. Ringsdorf model of a polymeric 
prodrug52. 
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Second, the solubilising group is responsible for how soluble the drug is in water, and therefore 
must be a hydrophilic group52. 
Third, the targeting group has the responsibility of making sure the polymeric prodrug reaches 
the desired site of pharmacological action. The targeting group has abilities that are dependent 
on a few different variables; the binding affinity for the ligand, the ligands internalization, non-
antibody ligands or antibody fragments, and the choice of antibody53. 
 
Fourth, the biodegradable spacer is responsible for monitoring the site of action and the 
dispersion rate of the active drug after it has been enzymatically/chemical activated via 
hydrolytic cleavage from the conjugate54. 
 
Fifth, also the final component in the Ringsdorf model of a prodrug is the drug itself. The drug 
must remain covalently bonded to the polymer backbone until the macromolecule arrives at 
the desired site of action. Drugs that are chosen for this role must fit three important criteria: 
(1) the drug must be suitably stable and must not be released in conjugate form before arriving 
at the desired site, and only then should it be released. (2) There must be a functional group 
present in the drug that allows it to bind via a space or directly to the polymer backbone. (3) 
The amount of drug that can be administered is limit, therefore the drug must be very potent55. 
 
1.2.2 Advantages of Polymeric Prodrugs 
Polymeric prodrugs have various advantages. One example is that through circulation around 
the body, the drug will eventually release a desired site of action, and only then will the drug be 
released at a controllable rate. The rate of release of the drug is controlled by having a specific 
type of linkage between the drug and the polymeric carrier, appropriate to the treatment. 
Controlling the release rate can be done in two ways, through pH or by the use of enzymes. With 
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the use of enzymes, the prodrug is taken up intracellularly, allowing the drugs to enter 
lysosomes that are present in healer and tumorous tissues. The enzymes within the lysosomes 
then act on the polymeric prodrug, resulting in the active macromolecular drug being released56. 
The cytotoxic drug then destroys any tumour tissue with the help of the enzymes57. Control 
using pH involves the use of a pH sensitive tracer such as N-cis-aconityl spacer, releasing the 
drug intracellular into tumour lysosomes or tissue when compared with healthy tissue58, 59.  
 
Another example of an advantage of a polymeric prodrug is their permeability effect and 
enhanced retention. These prodrugs are passively absorbed by solid tumours via pinocytosis 
which improves the targeting ability of the drug60. The tumours have increased vascular 
permeability and have poor drainage from tissue cells, these properties are what allow for an 
increased action duration and targeting ability61.  
 
The active targeting of polymeric prodrugs means that, via the endothelial cells, the angiogenic 
vessels of cells that are tumorous can be targeted. This is because the cell proteins appear to 
manifest at an increased level. Integrin receptors are present in these proteins along with 
receptors responsible for vascular endothelial growth factor (VEGF) 62. There are potential 
targeting groups that are peptides that are able to bind to these receptors specifically and 
selectively63.  Lectins can also be targeted using targeting groups in polymeric prodrugs because 
they are sugar specific receptors that are present in cells on the plasma membrane. Hepatocytes 
are an example of cell that these receptors are a characteristic of64.  
 
The increased drug action duration in polymeric prodrugs is because of their slower renal 
elimination and because they are metabolically inactive. The length of action of these prodrugs 
is measured by plasma concentration, which is usually calculated as the area under curve (AUC). 
Through allowing the drug to link to a polymer, therefore obtaining a conjugate, the duration of 
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action can be extended. This slows down the endocytotic cell uptake, renal excretion and blood 
circulation of the drug65-67. 
 
With polymeric prodrugs, the immunity of a patient can be protected because of a mechanism 
known as Fas-Fas Ligand (Fas L) interaction68. These ligands are present on cancerous and 
immune cells, and interacting with the Fas L can result in the apoptosis of a cell (death) via a 
torrent of signals69. Studies reveal that the stimulation of Fas L on cancerous cells can be 
encouraged with free anti-tumour treatment, but not with their macromolecular derivatives. 
These results show the potential of polymeric prodrugs with regards to the protection of a 
patients’ immune system70.   
 
1.3 Hydrogels as a Drug Delivery System 
Hydrogels have a massive array of uses in a vast degree of fields such as drug delivery systems71, 
biomolecule or cell separation72, pharmaceuticals73, tissue engineering and regenerative 
medicines74, diagnostics75, biomedical applications76, biosensors77, wound dressing78, sealing79 
and regulating biological adhesions through becoming barrier materials80. Some gels can have a 
low water content, but typically hydrogels contain a large percentage of water (up to >90%) 
making them very biocompatible and these materials are physically or chemically crosslinked81. 
There are various ways to achieve this macromer crosslink; examples being through radiation 
exposure, temperature change or with the use of chemical crosslinkers82, 83. With the presence 
of a radical initiator, a chemical crosslink can be achieved when di-functional or multi-functional 
grouped crosslinking agent links to two or more monomer chains (shown in Fig. 1.5)84. These 
materials are excellent for drug loading due to their porous nature, and the rate of release of 
the drug is directly correlated with the diffusion rate of the hydrogel through the matrix. The 
density of the crosslink can also be controlled, allowing for the fine tuning of the rate of 
diffusion, resulting in continual drug release at a localized depot85.  
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On the other hand, hydrophilic drugs such as proteins have a higher probability to diffuse out of 
the gel due to the high water content of the hydrogels. This diffusion can happen in just hours, 
up to days86, 87. This problem can be solved using a cleavable linker, with the covalent binding of 
the hydrophilic drug to the hydrogel, thus increasing delivery time. As a result, the rate of 
release of the drug is directly correlated to the rate of hydrolysis of the cleavable linker86, 87.  
 
 
 
 
 
 
 
 
 
 
 
1.3.1 Types of Hydrogels and Categorisation 
There are many types of hydrogels, which can be synthesised in a variety of ways and can be 
categorised through a number of ways. Hydrogels can be categorised based on what source they 
are from, being either synthetic or natural89. 
 
They can also be categorised depending on their composition of polymers: 
(1) Polymeric hydrogels that are Multipolymer Interpenetrating (IPN) are formed from two 
natural and/or synthetic polymer components that are independent of each other and are cross-
Fig. 1.5. HA/Pluronic® hydrogels slightly cross-linked 3-D network 
formation and their sol-gel transition characteristics88. 
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linked, contained in a form of network. These polymers can also have one being non-cross-
linked and the other being cross-linked, making the hydrogel semi-IPN90.  
(2) Hydrogels that are copolymeric consist of at one or more hydrophilic components with two 
of more monomer species that are different to each other, which have an alternating, block or 
random configuration arrangement along the polymer network chain91.  
(3) Hydrogels that are homopolymeric, meaning one species of monomer making up the whole 
polymer network, which is the structural unit that is most basic. Depending on the technique of 
polymerization and the monomer nature, these types of polymers can have a cross-linked 
skeletal structure92.  
 
Hydrogels can be categorised based on electrical charge absence or presence on the cross-linked 
chains. These hydrogels are organised into groups being zwitterionic where the structural 
repeating units have both cationic and anionic groups present. They can be an amphoteric 
electrolyte having both basic and acidic groups present. Finally, the hydrogels can be ionic or 
non-ionic in nature, meaning they have positive/negative charge or are neutral respectively93. 
They can also be classified according to their chemical composition and physical structure, being 
crystalline, amorphous (non-crystalline) or semi-crystalline which is a complex mixture of the 
two93. 
 
1.3.2 Advantages of Hydrogels 
Hydrogels have alternate methods of use when combined with other drug delivery methods 
such as liposomes or lipid microtubules94, 95. In microsphere systems, the drug is often released 
in a single burst, however, in hydrogel systems this does not occur and the drug particles may 
remain at the site of desired treatment. The release times of the hydrophilic molecules are 
increased by hydrophobic liposomes or microspheres96. Many hydrogels can transition into a 
gel in situ through an increase in temperature through body heat, this is because the polymers 
 
25| P a g e  
 
have a lower critical solution temperature, thus forming a gel upon entry into the body. This 
phase transition process can be known as the sol-gel (lower) and gel-sol (upper) transitions. In 
addition, this phase transition is reversible in some gels97. 
 
 
 
 
 
 
 
 
 
 
 
 
 
In temperature sensitive gels, the sol-gel phase transition describes the temperatures at which 
a specific type of polymer gel changes from a solution to a gel. More specifically, triblock co-
polymer gels transition from a solution to a gel at body temperatures (around 37°C) and can 
transition back to a solution again at higher temperatures, as shown above (Fig. 1.6). The lower 
sol-gel transition mechanism is known to be caused by the increasing amount of micelles that 
form as the temperature increases, which then aggregate together, giving rise to a more closely 
packed system (gel). On the other hand, the upper gel-sol transition occurs when the 
temperature continues to increase further, causing the hydrogen bonds between the PEO 
chains and the water molecules that are present to get weaker, thus resulting in de-swollen 
micelles and the removal of the close packing constrains. It was observed that as the 
Fig. 1.6. Sol-gel phase diagram example of a triblock co-polymer in 
aqueous solution. The sol-gel transitions are shown as the circles, 
and the squares represent the temperatures at which the gel 
becomes turbid, acquired from references98. 
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hydrophobicity of the triblock co-polymers increased, the critical gel concentration and sol-gel 
transition temperatures decreased99. Alternatively, polymers such as alginate or chitosan form 
gels through either the addition of salts or pH changes due to their ionic interactions100.    
 
On the other hand, hydrogels can be synthesised via light induced formation. This is done 
through monomers being exposed to a photo-initiator, which are compounds that are sensitive 
to light and generate free radicals when exposed to light in the UV/vis range, thus commencing 
polymerization via active sites on macromer chains as a result101, 102. With regards to photo-
polymerization, the spatial and temporal dimensions can be tuned in the process of 
polymerization, giving it advantages over other types of polymerization103. Prior to 
polymerization, the desired shape of construct can be achieved using a mould or defect of 
choice due to the liquid form of the polymer. A specific gelling depth can also be achieved via 
changes in light intensity and exposure time. Appropriate bioactive cells or factors can also be 
mixed with the photo-curable hydrogels upon injection using a syringe, much like temperature 
or chemical crosslinking103-107 In addition, the delivery system will be completely eliminated from 
the body after a period of time if biodegradable or bioresorbable materials are used for the 
synthesis of the hydrogels108. Hydrogels have further advantages within the field of tissue 
engineering specifically because they decrease the number of surgical procedures required to 
treat an illness, improving the morale of patients109.  
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1.3.4 Fluorescent Dyes in Hydrogels 
Through the addition of fluorescent microbeads, hydrogels have the capacity to become 
fluorescent. A recent study revealed that these types of hydrogels have huge potential for in 
vivo glucose monitoring, uninterrupted, with wireless transdermal transmission and a long 
lasting activity110. These fluorescent materials are not yet understood deeply enough as they 
still have a lacking intensity in transdermal transmission and maternal toxicity. A study led by 
Hideaki et al. showed a fluorescent monomer was synthesised that had polymerization sites, 
glucose-recognition sites and a fluorogenic site110. The spacers were designed to be long and 
hydrophilic in an attempt to allow more glucose molecules to bind to the monomer. Therefore 
these fluorescent monomers result in a high-intensive responsiveness to glucose. Fluorescent 
polyacrylamide hydrogel beads that were injectable-size were synthesised that had high 
throughput and high uniformity. It was established that these fluorescent microbeads had a 
sufficient fluorescent emission intensity to transdermally monitor concentrations of glucose in 
vivo110.   
Alternatively, a study led by Wang et al. showed the building blocks of a polymer being joined 
together with a DNA template, forming a DNA-conjugated polymer composite hydrogel. The 
delocalised electron structure of the conjugated polymer caused the hydrogel to exhibit 
fluorescence. This fluorescence was shown to be quenched by the addition of a drug, and this 
fluorescence returned once the drug had been dispersed. These characteristics show very useful 
applications for scientists, as they can view and keep track of the hydrogel fluorescence during 
in vitro experiments, revealing information on the amount of drug that a hydrogel will be likely 
to distribute after administration on humans111. 
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1.4 Pluronic® Surfactants for Preparing Hydrogels 
The term ‘Pluronic®’ is used to described triblock copolymers that are water soluble, with the 
structure PEO-PPO-PEO. The PEO is an abbreviation of poly(ethylene oxide) and PPO of poly 
(propylene oxide). It is their potential intrinsic biological activity and already attractive 
fundamental properties that are responsible for the extensive use of these amphiphilic block 
copolymers in the field of nanomedicine112. Modifying the molar mass ratio between the PPO 
and PPE can alter the interactions that these Pluronic® copolymers have with cell 
membranes/cells and can change the in vivo properties. This allows for the fine tuning of their 
chemical and physical properties, creating growing prospects for the design of novel 
biomaterials and innovative nanomedicines112.  
 
These materials are formed by micelles above the critical micelle concentration (CMC). These 
compounds are non-ionic surfactants that are highly active on the surface113, 114. The highly 
temperature-dependant nature of the propylene oxide and ethylene oxide blocks will result in 
the triblock copolymer being formed, when the CMC is dropped drastically through an increase 
in temperature115. The parameter used with regards to micelles is known as the critical micellar 
temperature (CMT), and the process of micellisation is reversible115, as shown below (Fig. 1.7). 
Pluronics® consist of two outer shells of PEO blocks that are hydrophilic, surrounding a 
hydrophobic core in the form of PPO that is weakly hydrated116, resulting in a copolymer that is 
amphiphilic117. In the micellisation process, the triblock copolymers rise to the surface of the 
water, and only once this layer has formed on top of the water will micelles begin to be 
formed117.  
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There are a few factors that can change the type of block copolymer that is formed, such as 
block size, temperature, solvent composition and molecular weight118. Pluronics® that have a 
higher molecular weight are usually formless solids, whilst those with a lower molecular weight 
tend to be creams or oils118. The presence of impurities and high hydrophobic constituents can 
be seen when Pluronics® behave abnormally, which can be attributed to the solvents that are 
chosen or exposure to unsuitable temperatures116, 119.  
 
1.4.1 Self-Assembly in Water 
The property that defines the term Pluronic® is the capability of the ‘unimers’, alternatively 
named as individual copolymer molecules, to undergo micellisation in aqueous solution. When 
the concentrations of the block copolymer are lower than the CMC, the ‘unimers’ form a 
molecular dispersion. Alternatively, micellisation will occur if the concentration of the block 
copolymer is higher than the CMC. It is the interactions of the PO blocks that are hydrophobic 
in nature that is the reason that micellisation happens. These hydrophobic PO blocks assemble 
themselves into the inner core of micelles, and the hydrophilic corona of the EO blocks is what 
Fig. 1.7. Formation of micelles as an overall mechanism for polymers. In triblock 
copolymers there will be two hydrophobic tails representing the PEO in PEO-PPO-
PEO 118.  
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surrounds them. This structure setup is usually depicted as a sphere for most block copolymers, 
when >30% of EO block content is present. This especially applies at body temperature with 
relatively dilute solutions. Depending on the type of Pluronic® used, the spherical micelles that 
form usually have a different average hydrodynamic diameter, varying from 20 up to 80 nm118. 
In addition, the number of ‘unimers’ that form into a single micelle can change from a few to 
over a hundred, this is known as the ‘aggregation number’120. 
 
1.4.2 Drug Solubilisation and Delivery 
Polypeptides and low molecular mass drugs are being investigated when solubilized into the 
Pluronic® micelles121. Solubilisation is the term used to describe the process of transferring 
water-insoluble compounds into the hydrophobic core of the micellar solution122-125. These 
polymeric micelles are effective carriers of compounds that typically would have undesired 
pharmacokinetics, low stability and poor solubility in a physiological environment. This is 
because of their essential core-shell architecture. The pharmaceutical behaviour of the block 
copolymer is improved greatly by the hydrophilic shell, allowing the micelles to maintain in a 
dispersed state, along with reducing the amount of unwanted interactions of the drugs with 
proteins and cells via steric-stabilization effects. In addition, the water-incompatible 
hydrophobic core formed by the PO chains create a sort of ‘cargo hold’ for specific therapeutic 
reagents that would otherwise not be feasible in these types of treatment (Fig. 1.8). 
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A polymeric micelle that is perfect for the job must show appropriate biological stability and 
compatibility, a great loading capacity and monitored drug release. However, the polymeric 
micelles have physiochemical characteristics that are completely dependent on the properties 
and lengths of the hydrophilic and hydrophobic blocks126. This results in an improved metabolic 
stability, solubility and circulation release time period of the drug127. Upon administration of the 
drug, the micelle concentration will rapidly decrease down to below the CMC, resulting in the 
concentration of the therapeutic agent decreasing also. However, it should be known that 
stability is compromised127.  
 
 
 
 
 
 
 
 
 
 
Fig. 1.8. Drug loading of a typical micelle ‘unimer’ using a hydrophobic 
drug. This is done via self-assembly126. 
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1.5 JEFFAMINES® for Functionalisation of C-dots 
Alternatively named as ‘polyetheramines’, these molecules consist of a polyether backbone 
with primary amino groups attached to each end. Propylene oxide (PO) and/or ethylene oxide 
(EO) are normally the constituents of the polyether backbone, giving the name 
‘polyetheramines’128.  
 
Up until recently, the JEFFAMINE® family contained core structures that were primarily 
monoamines, diamines and triamines. However, this unique range of product now has improved 
utility, with polytetramethylene glycol (PTMEG) based JEFFAMINES® emerging128. The diamine 
JEFFAMINES® have EDR, ED, and D series products. These molecules are defined and named 
with their molecular weight, with the D Series JEFFAMINES® named as D230 or D400 for 
example, with the D signifying a diamine. The EDR signifies a PEG based diamine that is highly 
reactive, and the ED represents a diamine with a predominantly PEG backbone. However, the D 
Series JEFFAMINES® are the only series that will be studied in this project, and are amine 
terminated PPGs with the following representative structure (Fig. 1.9)128, with the x indicating 
the number of repeats along the polymer backbone: 
 
 
 
 
 
 
These polyetheramines usually engage in typical amine reactions, regularly showing low 
viscocity and colour, increased toughness and increased flexibility. The variables in these 
JEFFAMINES® include different repeating unit types, distribution, amine functionality and 
Fig. 1.9. D Series JEFFAMINE® representative structure128. 
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varying molecular weight, resulting in the designing of new mixtures or compounds to be very 
flexible128. 
 
1.6 Paracetamol for Drug Release Profiles 
Paracetamol (PCL) is known as a mild analgesic and anti-pyretic drug129. It has the chemical name 
para-acetylaminophenol, shown below (Fig. 1.10). It has insignificant anti-inflammatory 
properties, but is an effective and regularly used drug to treat fever and pain130.  This drug is 
typically administered orally or rectally, and is soluble in water. However, it has a low solubility 
in water in comparision to other polar solvents such as alcohols131. The side effects of an 
overdose of PCL include a loss of appetite, diarrhoea, nausea, increased sweating, stomach 
cramps/pain, and swelling/pain/tenderness in the upper abdomen area132. 
 
 
 
 
 
 
Paracetamol is absorbed very effectively in the gastrointestinal tract. However, bioavailability 
via oral administration is dependent on the dose.  The highest concentration of the drug in blood 
plasma is reached within less than two hours. Paracetamol also has a half-life of two and a half 
hours, resulting in the need for regular doses to maintain the therapeutic effect for longer 
periods of time133.  
 
 
 
 
Fig. 1.10. The chemical structure of 
Paracetamol (para-acetylaminophenol) 134. 
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1.7 Ibuprofen for Drug Release Profiles 
Ibuprofen (IBU) is classified as a non-steroidal anti-inflammatory drug (NSAID). Although its 
commercial name is widely used, this drug has the chemical name of 4-isobutyl-α-
methylphenylacetic acid135, shown below (Fig. 1.11). IBU is primarily recognised for its anti-
inflammatory, anti-pyretic and analgesic properties136. It is much more soluble in most organic 
solvents in comparison to water137. Primarily ingested orally, IBU can reach peak plasma 
concentration in two hours with the use of conventional tablets. With a half-life of 2 hours, 
regular doses of the drug must be administered to maintain therapeutic effect, similarly to 
paracetamol136.  
 
 
 
 
 
 
With both drugs having issues maintaining therapeutic effect for longer periods of time, the 
incorporation of a polymeric prodrug can be done by covalently attaching it to the drug via 
chemical or physical linkage, allowing for the release of the drug to be monitored138. 
 
The drugs ibuprofen and paracetamol were chosen as examples of model drugs, to study the 
potential interactions that the C-dots have with the release profiles of these drugs. 
 
 
 
 
 
Fig. 1.11. The chemical structure of Ibuprofen (4-isobutyl-α-
methylphenylacetic acid)139. 
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1.8 Research Project Objectives 
The objective of this study will be to synthesise the EA-CA carbogenic nanoparticles and to 
functionalise them with various types of JEFFAMINES®, to use them in conjunction with 
Pluronic® P-123 32.5 wt% hydrogels as a drug carrier. These types of C-dots will be used due to 
their fluorescence properties, biocompatibility and as a potential medium to control the release 
rate of model drugs. In addition, the fluorescence characteristics of these varying types of C-
dots will be tested and compared. The functionalisation of C-dots with JEFFAMINES® will 
represent the polymeric backbone in a drug delivery system that will be similar to that of a 
polymeric prodrug. 
 
Finally, therapeutic drugs ibuprofen and paracetamol will represent model drugs to be 
incorporated into a polymeric prodrug system. They will be dispersed into Pluronic® gels with 
different types of C-dots, to produce various drug release profiles also to be compared. This 
project will be an attempt to achieve controlled and sustained drug delivery whilst 
simultaneously allowing for real-time in vivo imaging to track the drug the location desired for 
therapeutic effect.  
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Carbogenic Nanoparticles 
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with JEFFAMINES® 
C-dots Functionalised 
with JEFFAMINES® 
+ 
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Hydrogel 
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1g C-dots 
Made to 10g with 
water 
  
Fig. 1.12. Schematic drawing illustrating the experimental process 
in this research project. 
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2. Materials and Methodology 
2.1 Materials 
Sodium Phosphate Dibasic (Na2HPO4) and Ibuprofen (4-isobutyl-α-methylphenylacetic acid) 
both bought from Alfa Aesar, UK.  
JEFFAMINES® D-230 and D-400 were provided by Alfa Chemicals, UK. 
Nitric acid 70% (HNO3) and Citric Acid Monohydrate (C6H8O7.H2O) were both bought from Fisher 
Chemical, USA.  
Ethanolamide ≥ 98% (C2H7NO), and PEG-PPG-PEG, Pluronic® P-123 (average Mn ≈ 5800 g/mol) 
were both bought from Sigma Aldrich, USA. 
Distilled, purified and deionised water taken from Elgastat Option 3 Water Purifier which was 
bought from ELGA LabWater.  
SnakeSkin® Dialysis Tubing, Internal diameter of 35 mm and a molecular weight cut-off of 3.5 
kDa was bought from Thermo Scientific, USA. 
2.2 Methodology 
2.2.1 Carbogenic Nanoparticles Synthesis (aC-dots) 
The protocol followed to synthesis the carbogenic nanoparticles in this research project was 
previously discovered by Marta Krysmann, Antonios Kelarakis et al.7-8 prior to the beginning of 
this research project. The same protocol was repeated in this project, and is as follows: 
 
With the use of a magnetic stirrer, 15ml of ethanolamine (EA) and 16.80g of citric acid 
monohydrate (CA) were mixed together in a round bottomed flask. This mixture of EA and CA 
was then initially heated using a hotplate at 180°C with a reflux condenser and left to reflux for 
30 minutes. After this time had passed, the mixture was heated for a further 60 minutes at 
230°C, and the reflux condenser was removed. The mixture was then transferred to a porcelain 
crucible whilst still hot and in liquid phase, to avoid solidification of the solution in the round 
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bottomed flask. This negates the need for water to be added to the mixture. This mixture was 
then calcined in the oven for 1 hour at 300°C. 
 
After the mixture was removed from the oven and left to cool to room temperature, what 
remained was a carbonaceous material that needed to be ground down with the use of a mortar 
and pestle. The now crushed solid particles were ran through a micro sieve with a mesh size of 
500µm to leave much smaller particles. These acquired carbogenic nanoparticles (CNPs) were 
dispersed in water and refluxed with nitric acid at 100°C for 16 hours. The solution formed was 
then filtered with standard filter paper to remove big agglomerates, and then placed in a 
centrifuge to facilitate the filtration step by further separating the CNPs from the big 
agglomerates.  
 
In the filtration step, the solution of CNPs is filtered using a nitrate membrane filter leaving 
particles that are 0.45µm in size. This filtered solution was then placed in dialysis tubing, which 
was placed in 2.5L of distilled water and left to pass through the tubing until the CNPs were 
purified by the removing impurities and by-products. The distilled water was replaced once per 
day and the purification process would take from a few days up to a couple of weeks to 
complete. The now pure solution was then stored in plastic bottles and frozen. After being left 
in the freezer for 24 hours, the bottles were placed in a freeze dryer, which took around 5 days 
to become completely dry and ready to be used in this research project.  
 
2.2.2 Functionalisation with JEFFAMINES® 
The method used to functionalise the C-dots with JEFFAMINES® involved the addition of 7g of 
JD-230 and JD-400 into two separate round bottomed flasks. Each JEFFAMINE® was mixed with 
5mL water with 0.2g of C-dots dissolved within it. Each mixture was heated to a temperature 
that was below the flash point of that corresponding JEFFAMINE® (128°C for D-230 and 163°C 
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for D-400)107 without a reflux condenser for 3 hours using a C-MAG HS7 hotplate. This was done 
to evaporate all of the water from the mixtures.  
 
Upon completion of the heating process, the mixtures were left to cool down to room 
temperature and then dispersed in water again to be placed in a Carbolite® furnace to be heated 
at 80°C for a few days until all water had evaporated again.  
 
The substance that remained was left to dialyse against deionised water using SnakeSkin® 
dialysis tubing. The water in the dialysis was replaced with fresh water multiple times per day, 
until no more impurities came out of the dialysis tubing. The purified products were then 
transferred into sample bottles to be freeze-dried until they were completely dry.  
 
2.2.3 Encapsulation of C-dots in Hydrogels 
The Pluronic® gels that were to have C-dots functionalised with JEFFAMINES® present had 15 
mg of the solid carbogenic nanoparticles added to 1g of Pluronic® gel and 9g water. The aC-dots 
were in solution at a concentration of 15.9 mg/ml, so 0.973 mL was used for each gel sample 
with aC-dots to make 15 mg/ml the standard concentration. The weight of the aC-dots solution 
was made up to 9g with water, and then 1g of P-123 was added to reach 10% w/t. The 
concentrations of the C-dots that were used in the pluronic gels were maintained at 15 mg/ml 
throughout the project. 
 
 
2.2.4 Gel Phase Behaviours 
The 32.5 wt% Pluronic® P-123 hydrogel were heated from 5°C to 80°C to distinguish the sol-gel 
and gel-sol phase transition temperatures, and to define the point at which the gels become 
turbid. The heating was done using a Grant Optima TC 120 circulation water bath.  
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2.2.5 Fluorescence Behaviours 
The Pluronic® P-123 32.5% w/t hydrogels with various types of C-dots were exposed to long 
wave UV light at a wavelength of 365 nm using a Model CM10A Fluorescence Analysis Cabinet 
(Spectroline) to test and photograph their fluorescent behaviour. In addition, using a Fluoromax-
4 Spectrofluorometer (Horiba Jobin Yvon), the aC-dots were ran through solid-like state 
fluorescence at 0.103 mg/ml in 32.5% w/t Pluronic® P-123 32.5% w/t. The samples were tested 
for their fluorescence properties at different excitation wavelengths (300, 340, 380, 420, 460, 
and 500 nm).  
 
The different types of C-dots were also analysed with liquid state fluorescence at various 
excitation wavelengths (320, 350, 380, 410, 440, 470 and 500 nm). Each sample of C-dots was 
maintained at a concentration of 0.05 mg/ml. In addition, fluorescence microscopy images were 
obtained at three excitation wavelengths (350, 395 and 590 nm) using a Zeiss Axio Scope A1 
Microscope with band-pass filters. The images that taken were compared with those of water.   
 
2.2.6 Pluronic® Hydrogel Preparation and Drug Loading 
As a standard, the hydrogels were made to 32.5% w/t using Pluronic® P-123 with a total mass 
of 10g. This gel was tested with different types of C-dots, observing the interactions of the C-
dots with primarily Ibuprofen and some testing with paracetamol.  
 
Ibuprofen will not disperse in the 32.5% w/t hydrogel so a 10% w/t gel must be made first to 
allow the drug to fully disperse and then the gel will be made up to 32.5% w/t. As it is very 
difficult to measure out 5mg of a drug without error, the mass of the total solution with the drug 
is multiplied by 10 up to a total of 10g with 50mg of drug. The 10% w/t was synthesised by 
adding P-123 to water at a ratio of 1:9 (1g P-123 to 9g water). Once the polymer had dissolved 
in the water, 50mg IBU was added and stirred using a magnetic stirrer until the drug had 
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completely dispersed. The hydrogel was made up to 32.5% w/t by adding a further 2.25g of P-
123 and then also stirred until the polymer had completely dispersed, leaving a gel at room 
temperature, but a solution when cold. 
 
To synthesise the hydrogel with ibuprofen or paracetamol, the same protocol is followed but 
the drug is added when the gel is at 10% w/t to allow the drug to disperse properly. 
Furthermore, the same protocol is also followed when using the various types of C-dots (aC-
dots, JD-230 C-dots and JD-400 C-dots), all of which are shown below (Table. 2.1). 
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Table 2.1. The masses used to synthesise Pluronic® hydrogels with varying C-dots and drugs.  
Pluronic ® Gels P-123 added to 
make 10% w/t 
(g) 
Drug Loaded (g) C-dots Added 
(g) 
P-123 added 
to make 
32.5% w/t (g) 
P-123 32.5% w/t 
 
 
1g - - 2.25g 
P-123 32.5% w/t 
+ IBU 
 
1g 50mg IBU - 2.25g 
P-123 32.5% w/t 
+ aC-dots 
 
1g - 1g aC-dots 2% 
w/t 
2.25g 
P-123 32.5% w/t 
+ JD-230 C-dots 
 
1g - 1g JD-230 C-
dots 2% w/t 
2.25g 
P-123 32.5% w/t 
+ JD400 C-dots 
 
1g - 1g JD-400 C-
dots 2% w/t 
2.25g 
P-123 32.5% w/t 
+ aC-dots + IBU 
 
1g 50mg IBU 1g aC-dots 2% 
w/t 
2.25g 
P-123 32.5% w/t 
+ aC-dots + P 
 
1g 50mg PCL 1g aC-dots 2% 
w/t 
2.25g 
P-123 32.5% w/t 
+ JD230 C-dots + 
IBU 
 
1g 50mg IBU 1g JD-230 C-
dots 2% w/t 
2.25g 
P-123 32.5% w/t 
+ JD400 C-dots + 
IBU 
 
1g 50mg IBU 1g JD-400 C-
dots 2% w/t 
2.25g 
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2.2.7 In Vitro Drug Release Studies 
These drug release studies were done at room temperature (20 ± 1°C), with Pluronic® hydrogels 
at 32.5 w/t using P-123. The studies were also done with and without the presence of various 
types of C-dots. The hydrogels when synthesised were moved separately into their own 
SnakeSkin® Dialysis Tubing membrane. Each dialysis tubing membrane was placed into 
individual beakers with 200mL of buffer solution at 7.4 pH (citric acid monohydrate and sodium 
phosphate dibasic) and at room temperature.  
 
The molecular weight of the P-123 when compared to the dispersed drugs is drastically larger, 
therefore the drugs were able to pass through the membrane into the buffer solution whilst the 
polymer could not. Samples of 1ml were taken from the solution surrounding the tubing, then 
placed in a glass sample vial, and the new volume was noted down to compensate for potential 
changes in concentration. These samples were taken at various time intervals at an attempt to 
plot a graph of drug release (0.25h, 0.5h, 0.75h, 1h, 2h, 3h, 4h, 24h, 48h, 72h, 96h 120h, and 
then every 3 days until the drug was 100% released).  
 
All samples taken were ran through a UV-3600 Spectrophotometer (Shimadzu) over a range of 
230-600 nm, and the concentration IBU that was released through the membrane was 
calculated. This calculation was done by plotting the levels of absorbance at the UV absorbance 
peak of IBU (ʎmax= 263 nm) against an IBU calibration curve.  
 
The calibration curve was devised by taking various concentrations of IBU ranging between 0.01 
and 0.9 mg/ml, then analysing their absorbance levels through the UV-Vis 3600 and plotting the 
spectra at ʎmax = 263 nm (as shown in Fig 2.1).  
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The samples were analysed in quartz cuvettes with 1.0 cm path length. These spectrums were 
plotted against a sample of the 7.4 pH buffer that was used in the dialysis as a blank. All samples 
were analysed at room temperature. 
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Fig 2.1. Ibuprofen calibration curve using various concentrations of IBU (0.01, 0.03, 0.05, 0.07, 
0.09, 0.1, 0.3, 0.5, 0.7, 0.9) in a phosphate buffer solution at pH 7.4. Absorbances taken at 263 
nm as determined by UV-vis spectra in conjunction with literature. 
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Fig 2.2. Paracetamol calibration curve using various concentrations of PCL (0.01, 0.03, 0.05, 
0.07, 0.09, 0.1, 0.3, 0.5, 0.7, 0.9) in a phosphate buffer solution. Absorbance taken at 243 nm as 
determined from UV-vis spectra in conjunction with literature. 
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3. Results and Discussion 
3.1 Characterization of Carbogenic Nanoparticles  
The protocol using citric acid and ethanolamine was followed to synthesise the C-dots that were 
used in this research project. This type of C-dot was abbreviated as aC-dots for purposes of 
efficiency. They have been previously characterised by Antonios Kelarakis, Marta Krysmann et 
al, confirming the legitimacy of their synthesis in this project.  
 
 
 
 
 
 
 
 
The synthesis of these C-dots was done with citric acid monohydrate and ethanolamine under 
pyrolysis at increasing temperatures (see methodology, p. 37), and resulted in the formation of 
carbogenic nanoparticles that have an average diameter of 8 nm (shown above in Fig. 3.1). 
These results concur with previous reports of C-dot synthesis using different pyrolysis 
methods140-144 and the size of these C-dots stay consistent even when exposed to major chemical 
changes. It is shown via TGA-MS experiments that in this system, a massive amount of carbon 
dioxide escapes during the 300°C stage of pyrolysis, which is accountable for the great reduction 
in size of the C-dots. Looking at the elemental analysis, the C-dots after being exposed to 300°C 
have a reduced amount of hydrogen and an increased amount of carbon when compared to the 
C-dots at 230°C, with a chemical composition of 50.5% C, 3.7% H and 13.1% N 3. 
 
Fig. 3.1 Tunnelling Electron Microscope images of the C-dots that were synthesised using the protocol in this 
project, and size histograms. Acquired from Reference3. 
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The C-dots appear to have a number of functional groups on their surface, due their capability 
to be well dispersed in water. This can be confirmed by looking at the FTIR spectra (shown below 
in Fig 3.2), showing that even after treatment at such a high temperature, there are clearly 
stable imide and amine groups remaining. However, the amount of these groups is significantly 
reduced when compared to the C-dots during pyrolysis prior to the 300°C stage of the process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.2. FTIR spectra to show the presence of imide and amide functional groups on the 
surface of the C-dots. Acquired from reference3. 
Fig. 3.3. Raman spectrum of C-dots after being exposed to a temperature of 300°C. 
Acquired from reference3. 
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The Raman spectrum of these C-dots show two peaks that dominate the spectra at 
approximately 1595 cm-1 and 1355 cm-1, which can be labelled as the G and D bands respectively 
of the carbon that is amorphous (shown in Fig 3.3). The graphite lattice has a signature of 
disorder, which is thought to be responsible for the D peak. The sp2 bonded carbon has an E2g 
vibration mode, which is responsible for the G peak. 
 
3.2 Fluorescence Properties of Carbogenic Nanoparticles   
After being exposed to UV light at wavelength 365 nm, images were taken of the Pluronic® P-
123 32.5% w/t hydrogel with aC-dots. The same protocol was done for diluted solutions (0.05 
mg/ml) of aC-dots and C-dots that were functionalised with JEFFAMINES® D-230 and D-400 
respectively, as shown below (Fig. 3.4.).  
 
 
Carbogenic nanoparticles have great fluorescence properties, especially with regards to the aC-
dots as shown above. Using the standard methods of preparation available to synthesise C-dots 
usually result in a very strong UV absorption peak. However, using different methods of 
preparation change these absorption peaks slightly, albeit still in the UV region. Using various 
Fig. 3.4. Images of the fluorescence characteristics of 32.5% w/t P-123 hydrogel samples with 
aC-dots, and dilute solutions of aC-dots, JD-230 C-dots and JD-400 C-dots respectively from left 
to right. The hydrogel was made at a concentration of 0.103 mg/ml and each dilute solution 
was maintained at 0.05 mg/ml. 
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methods of preparation, C-dots of varying sizes have been synthesised with differing 
fluorescence characteristics: 
 
Fluorescent C-dots that were synthesised by Dong et al. at 200°C via citric acid carbonisation. 
These nanoparticles were observed to see diameters of 15 nm, and when analysed with a UV-
Vis spectrophotometer, they exhibited a thin peak at 362 nm. It was also observed that when 
the C-dots were exposed to various excitation wavelengths, it did not change the highest 
emission level145. 
 
On the other hand, fluorescence C-dots that were water-soluble were prepared by sonicating a 
mixture of 70 mL hydrogen peroxide and 4.0 g of active carbon for 2 hours at approximately 
room temperature by Li et al. These nanoparticles were observed to see a diameter range of 5-
10 nm, exhibiting a UV-Vis band peak at 250 – 300 nm showing the absorption of an aromatic 
pi system146.   
 
With the use of a simple solvothermal technique, Jiang et al. exposed three types of C-dots to 
UV light at single excitation wavelengths, producing blue, green and red fluorescence. It was 
established that the photostability of all the C-dots in ethanol was good, but when the 
nanoparticles were exposed for an hour to UV light at wavelength 365 nm, the photostability 
was slightly decreased (by < 5%)147. 
 
C-dots that were synthesised by Wang et al. involved vigorously mixing N-(β-aminoethyl)-γ-
aminopropylmethyldimethoxysilane (AEAPMS) solution with half a gram of citric acid for 60 
seconds at 240°C. The nanoparticles that were synthesised had an average diameter of 0.9 nm 
and upon analysed using UV-Vis they exhibited an intense absorption peak at 360 nm148.  
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3.2.1 Fluorescence Spectra of Carbogenic Nanoparticles 
With excitation wavelengths ranging from 300 – 500 nm in the solid-like state fluorescence, it is 
clear that the strongest levels of fluorescence are from the excitation wavelengths that are in 
the UV region, with the maximum intensity being at 380 nm excitation. The emission wavelength 
peaks do not shift significantly with the change of excitation wavelength, showing the presence 
of fluorophores because they fluoresce independently of excitation wavelength (shown in Fig. 
3.5). The aC-dots solution was made up to a concentration of 0.103 mg/ml because this was 
necessary to be able to see significant enough peaks in the fluorescence spectra.  
 
 
Kelarakis et al. used the same protocol of C-dot preparation to analyse the fluorescence levels 
of these C-dots at various temperatures (180, 230 and 300°C) and at excitation wavelengths 
ranging from 275 to 600 nm, increasing in 25 nm increments. Solutions were maintained at 0.1 
mg/ml and it was found that the maximum intensity was observed for the excitation wavelength 
of 375 nm for the C-dots at 180°C and 230°C. This was not the case for the C-dots at 300°C 
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Fig. 3.5. Solid state fluorescence spectra of Pluronic® P-123 32.5% w/t hydrogel with 0.103 mg/ml aC-dots at 
excitation wavelengths 300, 340, 380, 420, 460 and 500 nm.   
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because at this temperature, the fluorescence comes from predominantly the carbogenic cores 
that form at higher temperatures, and the fluorescence levels are no longer dominated by the 
fluorophores. At this temperature, the highest intensity level was observed at an excitation 
wavelength of 275 nm8. The solid-like state fluorescence spectra above was done at room 
temperature, resulting in fluorophores being a significant contribution to the levels of 
fluorescence.   
 
In liquid state fluorescence, the maximum emission intensity of the dilute solution of aC-dots is 
very similar the 32.5% w/t Pluronic® gel with aC-dots spectra. However, the concentration of 
the aC-dots in the liquid state fluorescence is half that of the solid state fluorescence.  
 
In the C-dots solution it is much easier for the nanoparticles to aggregate together when 
compared to the C-dots in the Pluronic® gel. This is because the gel acts as a significant enough 
separating agent to keep the nanoparticles apart, stopping them from aggregating, thus 
maintaining good dispersion. This aggregation of nanoparticles in the C-dots solution creates 
clusters of C-dots, resulting in a poor dispersion of the C-dots, therefore potentially decreasing 
fluorescence emission intensity.  
 
With the 0.05 mg/ml solution of aC-dots in water, the maximum emission intensity peaks at 
different excitations have not changed position for excitation wavelengths 320, 350, 380 and 
410 nm. This suggest the presence of ʎex independent fluorophores. All of the fluorescence 
emission peaks appear to have red-shifted somewhat.  
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The C-dots that were functionalised with JEFFAMINES® D-230 and D-400 were also analysed 
using liquid state fluorescence spectroscopy. The JD-230 and JD-400 C-dots showed similar 
spectra plots to each other, which is to be expected as they have the same fundamental 
structure with different molecular weights. These types of C-dots exhibited significantly lower 
intensity levels when compared to the aC-dots.  
Fig. 3.6. Liquid state fluorescence spectra of a 0.05 mg/ml solution of aC-dots with water at excitation 
wavelengths 320, 350, 380, 410, 440, 470 and 500 nm. 
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Fig. 3.7. Liquid state fluorescence spectra of a 0.05 mg/ml solution of JD-230 C-dots and water at excitation 
wavelengths 320, 350, 380, 410, 440, 470 and 500 nm. 
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This suggests a decrease in the amount of fluorophores present in the solution, which is 
supported when looking at the fact that the emission peaks in the C-dots functionalised with 
JEFFAMINES® are shifting as the excitation wavelengths change. Fluorophores fluoresce at the 
same wavelength regardless of the excitation wavelength, making them ʎex independent. The 
shifting of maximum intensity peaks with changing excitation wavelengths shows the decrease 
in fluorophore levels, meaning the fluorescence is caused primarily by the C-dots which are ʎex 
dependent.  
 
The liquid state fluorescence of JD-400 C-dots shows a further decrease in maximum intensity 
levels when compared to the JD-230 C-dots. This suggests the possibility that the increasing size 
of the particles can decrease the amount of space available for the fluorescent C-dots when 
using equal quantities of each type of C-dot with the Pluronic® 32.5 wt% P-123 gels. In addition, 
although the amino groups that are present on the JEFFAMINES® have been established to 
improve fluorescence levels, there are only two amino groups on each JEFFAMINE® molecule. 
This further suggests that as the polymer size increases, the ratio of amino groups to the size of 
the chain decreases, therefore decreasing the effectiveness of the improved fluorescence levels 
that the amino groups can potentially provide. 
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With the fluorescence intensity peaks shifting position with the changes in excitation 
wavelength, this further supports the presence of primarily excitation dependent fluorescent 
carbogenic cores. The magnitude of shift in the maximum intensity peaks is almost identical to 
that of the JD-230 because they are of the same structures, but with different molecular mass.  
 
In comparison, a study conducted by Wang et al. involved experiments on C-dots that were 
synthesised using JEFFAMINES® T-3000 and T-5000 as a carbon source, without a passivation 
agent. After 15 heating-cooling cycles for 45 min each in a 300W microwave, the organic 
compound changed from a transparent to a dark brown solution. Upon the addition of 1 mL of 
deionised water to this solution, the C-dots were extracted via the use of a centrifuge. Finally, 
the C-dots were well dispersed in an aqueous supernatant that was golden-yellow in colour. 
These two types of C-dots were exposed to UV-light to display a blue fluorescence, showing 
emission peaks that were centred at 448 nm and 439 nm for the JT-3000 and JT-5000 C-dots 
respectively. The maximum intensity peaks had a broad range in the visible light spectrum, 
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Fig. 3.8. Liquid state fluorescence spectra of a 0.05 mg/ml solution of JD-400 C-dots and water at excitation 
wavelengths 320, 350, 380, 410, 440, 470 and 500 nm. 
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varying from 400 nm to 500 nm with a range of excitation wavelengths from 325 nm to 405 nm. 
In this experiment, it was established that the JT-3000 and JT-5000 C-dots had a 
photoluminescence that was ʎex dependent149.  
 
3.2.2 Fluorescence Microscopy Images 
Using a Zeiss Axio Scope A1 microscope with band pass filters, sample vials of water, aC-dots, 
JD-230 C-dots and JD-400 C-dots were exposed to three excitation wavelengths (350, 395 and 
590 nm respectively) and these fluorescence microscopy images were obtained. The light 
pathways through the samples were observed and fluorescence properties were compared. As 
a standard, these characteristics were compared with the light pathways through water. 
 
The fluorescence microscopy images of aC-dots, JD-230 C-dots and JD-400 C-dots when exposed 
to light at wavelengths 350, 395 and 500 nm (respectively from top to bottom) clearly show 
distinct light pathways through the C-dot solutions in comparison to water, as shown in (Fig. 
3.9). The first thing to be noticed is that the when the aC-dots were exposed to light at 
wavelength 350 nm (Ultraviolet), they fluoresce a darker blue compared to the C-dots 
functionalised with JEFFAMINES® fluorescing light-blue/white.  
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This is supported by the fluorescence spectra of these C-dots (see Fig. 3.6, 3.7 and 3.8), showing 
that the maximum intensity peaks of the JD-230 and JD-400 C-dots at excitation wavelength 350 
nm have shifted to the left, more towards the UV region of the spectrum. In addition, the 
fluorescence intensity of the aC-dots when exposed to light at wavelength 395 nm (Green) is 
significantly higher than that of the C-dots functionalised with JEFFAMINES®. This can be 
supported by looking at the maximum intensity peaks on the fluorescence spectra at excitation 
Fig. 3.9. Fluorescence microscopy images of sample vials with water, aC-dots, JD-230 C-dots and 
JD-400 C-Dots when exposed to light at wavelengths 350, 395 and 590 nm using a fluorescence 
microscope with band-pass filters. The top row of images show water, 2nd row aC-dots, 3rd row JD-
230 C-dots, and bottom row JD-400 C-dots.  
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wavelengths 380 and 410 nm, both of which have significantly higher emission intensities in aC-
dots than the JD-230 and JD-400 C-dots.  
 
A study lead by  Baker et al. involved C-dots that were synthesised by a one-step laser 
passivation method. It was shown that C-dots that were synthesised by laser ablation only 
exhibited fluorescence emission upon being surface passivated by specific organic moieties, 
whether in solid state of dispersed in solution. Therefore, the C-dots were in aqueous solution 
and were passivated with PEG1500N. The C-dots were excited at 400 nm with images taken 
through band-pass filters of wavelengths 400, 450, 500, 550, 600, 650 and 690 nm. Images were 
also taken directly upon the excitation of the C-dots at the same wavelengths. The C-dots in this 
study exhibited a strong ʎex dependence, resulting in the emission peaks red shifting with 
increases in excitation wavelength26. This strong dependence on λex does concur with the 
fluorescence images and spectra in this project. However, the colour-shift occurred in the 
opposite direction, showing the widely contrasting fluorescence behaviours of different types 
of C-dots. 
 
3.3 Gel Phase Behaviour 
To determine the gel phase behaviours of 32.5 wt% Pluronic® P-123 hydrogels with the presence 
of different types of C-dots, the gels were heated from 5°C to 75° to establish the temperatures 
at which the sol-gel (lower) and gel-sol (upper) transitions occur. These transitions were 
determined for P-123 hydrogels with JD-230 C-dots and JD-400 C-dots, aC-dots and without C-
dots (shown in Fig 3.10).  
 
The JD-230 C-dots and aC-dots did not affect the sol-gel transition temperature, but the JD-400 
did affect it significantly, reducing it by 10°C. However, the gel-sol transition temperature varied 
depending on the type of C-dots that were present, with all types of C-dots increasing the 
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temperature by different amounts. With the gel-sol transition temperature of P-123 32.5 wt% 
hydrogel starting at 62°C, the aC-dots, JD-400 C-dots and JD-230 C-dots increased this transition 
temperature by 2°C, 4°C and 6°C respectively. In other words, the incorporation of C-dots does 
not compromise the highly desirable injectable nature of the Pluronic® gels, given that the C-
dot based gels also exhibit a sol-gel transition below body temperature. This behaviour can in 
principle allow the injection of a sol system (avoiding the need for a surgical treatment) that 
instantly becomes immobile to the home body, offering localised and targeted treatment. 
 
 
 
 
 
 
 
 
 
 
A study led by Jeong et al. confirmed that the sol-gel and gel-sol transitions are influenced 
significantly by the concentration of polymer present. The method they used yielded the phase 
transition temperatures of Pluronic® gels to an accuracy of ± 0.5°C.  For the lower sol-gel 
transition, this was done with gel concentrations of 17 - 40 wt% that were exposed to a gradual 
temperature decrease to 30°C from 36°C. It was shown that this transition was highly 
concentration dependent. For the upper gel-sol transitions, the same varying concentrations of 
polymer gels were subjected to increasing temperature from 44°C to 70°C, also revealing that 
the transition temperatures were concentration dependent99.   
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Fig 3.10. Gel phase behaviours of 32.5% w/t P-123 hydrogels with the presence of various types 
of C-dots and without any C-dots, shown in the form of a histogram. 
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3.4 Drug Release Studies 
3.4.1 Ibuprofen Calibration Curve 
To begin studying the release rates of IBU in Pluronic® P-123 hydrogels with the presence of 
various types of C-dots, an IBU calibration curve must be plotted to do calculations against later. 
The calibration curve was done by preparing samples of IBU in increasing concentrations of 0.01, 
0.03, 0.05, 0.09, 0.1, 0.3, 0.5, 0.7 and 0.9 mg/ml in a buffer solution of citric acid and sodium 
phosphate dibasic at a pH of 7.4. UV-vis spectroscopy indicated that the maximum absorbance 
occurs at 263 nm, in agreement with literature. Therefore, the absorbance at 263 nm was taken 
to plot the calibration curve (see Methodology Section – Fig 2.1).  
 
Each gel had a total weight of 10g, with 50mg of IBU present in the mixture, meaning the 
standard concentration of IBU in each mixture was 0.5 wt%. This concentration of IBU was 
consistent throughout all gels, including those with the presence of aC-dots, JD-230 C-dots and 
JD-400 C-dots. The release profiles of IBU in all of these gels were observed at room temperature 
against 200mL of 1.0 M buffer solution at pH 7.4. Each process of dialysis was left for a long 
period of time with frequent samples taken to study the rate of release of IBU. 
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3.4.2 Release Profiles without C-dots 
In each mixture, regular samples were taken over a long enough period of time so that the IBU 
could reach the maximum release percentage achievable for that mixture. In this experiment, 
the polymer appears to remain inside of the dialysis tubing due to its molecular weight cut-off 
of 3.5 kDa, and the IBU had no issue passing through. There were a negligible amount of 
fluorophores that had passed through the tubing into the PBS 7.4 pH, because the solutions 
were the same colour before and after dialysis. Except with the C-dots functionalised with 
JEFFAMINES®, in which the buffer solution changed to a very pale yellow, almost clear. 
  
In the various dialysis experiments, it is clear that the presence of C-dots and what type of C-
dots they were, did significantly affect the IBU total release percentage and the rate at which 
IBU was released. With regards to the Pluronic® gel without any C-dots present, the drug 
appears to be burst released up to ≈35% within the first 3 hours and continues to be released 
rapidly, reaching a maximum release of 60-65% within 24 hours in both attempts (as shown in 
Fig. 3.12).  
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Fig. 3.12. Release profiles of Ibuprofen from Pluronic® P-123 hydrogels against a phosphate buffer solution (pH 
7.4) at room temperature, without the presence of any C-dots. 
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3.4.3 Release Profiles with C-dots 
  
 
  
The cumulative drug release percentages were calculated by taking the absorbance levels at 263 
nm for Ibuprofen as the y value in (𝑦 = 𝑚𝑥 + 𝑐)  , then rearranged to calculate 𝑥. This value 
was then multiplied by the total volume of solution outside of the dialysis tubing, then 
multiplied by 1000 to translate the decimals into percentages.  
 
Looking at the release profiles of IBU in P-123 hydrogels with various C-dots (shown in Fig. 3.13), 
the drug release from the aC-dots and JD-230 C-dots indicate the most gradual rates of release. 
The aC-dots show a sustained rate of release throughout dialysis, gradually reaching 29% drug 
release within 24 hours, and reaching a maximum release of approximately 77%. The JD-230 
exhibit a very similar trend, but reach a maximum release of ≥ 95% after about 2 weeks, showing 
an enhanced drug release in comparison to the gel with aC-dots. The gels with JD-400 exhibit 
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Fig. 3.13. In vitro release profiles of Ibuprofen from Pluronic® P-123 hydrogels against a phosphate buffer solution 
(pH 7.4) at room temperature. The squares represent the gel without the presence of any C-dots. The circles, 
diamonds and triangles represent the gels with JD-230 C-dots, JD-400 C-dots and aC-dots respectively.  
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burst release at the start, up to 19.5% in the first 15 minutes, releasing about 30% within 24 
hours, then a gradual release to reach a maximum drug release of ≥ 95% after 2 weeks.  
 
It is clear that the maximum drug release percentage of the gels with C-dots functionalised with 
JEFFAMINES® is higher than that of the gels with aC-dots. This increase in release could be due 
to the release of the close packing constrains, along with the possibility of effective channels 
forming that can facilitate the diffusion of the drug out of the gels. These plots show that in 
Pluronic® hydrogels, the presence of different types of C-dots not only slows the rate of release 
down to a more controlled and sustained rate, but also allows the drug to reach a higher release 
percentage, showing enhanced drug release when compared to the Pluronic® hydrogels without 
C-dots. The most successful drug release profile appears to be that of the Pluronic® P-123 
hydrogel with C-dots functionalised with JEFFAMINE® D-230, with the highest maximum drug 
release of indicating a slow and sustained rate of drug release through the dialysis tubing over 
the course of 4 weeks. In addition, this drug delivery system exhibited the most enhanced drug 
release due to its maximum drug release percentage being the highest.   
 
A study conducted by Liu et al. showed experiments observing the release of Docetaxel (DTX) in 
vitro. With the use of Tween 80-free as a medium to improve the solubility of DTX, the drug was 
loaded into Pluronic® P-123. Using a dialysis bag with a molecular weight cut-off of 8-14 kDa, 
the drug was dialysed at 37°C against a buffer solution at pH 7.4. After 24 hours, the DTX reached 
84.05% released. The drug was released via diffusion and dissolution from the DTX micelles, and 
it was established that the DTX delivery system was effectively influenced by the P-123 
micelles150. 
 
Similarly, experiments with similar parameters were conducted by Han et al. observing the in 
vivo and in vitro of paclitaxel (PTX) which was also loaded into Pluronic® P-123. Using the 
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method of solid dispersion, the drug was dispersed within the P-123, filtered and then freeze-
dried. The remaining substance was then dissolved again into water, and 1mL of this solution 
was dialysed against 50mL of sodium salicylate at a concentration of 1 mol/L at 37°C for 24 
hours. The dialysis tubing had a molecular weight cut-off of 5 kDa. Approximately 40% of the 
drug was released in the first 4 hours, and reached a maximum release percentage of 87.8% 
within 24 hours. Using this data, Pluronic® P-123 was shown to be an effective candidate for the 
carrying of insoluble drugs. It also increases the half-life of the drug by controlling the release 
delivery system151.  
 
Alternatively, a research project led by Jeong et al. studies the drug release profiles of 
spironolactone and ketoprofen, which both had hydrophobic properties that were different. 
These drugs were release from PEG-PLGA-PEG triblock copolymer hydrogel formed in situ by 
injecting these solutions into aqueous environments at 37°C. It was shown that the ketoprofen 
had a first order release profile, exhibiting burst release up to 40% within the first 24 hours and 
reached a maximum drug release of about 90% within 1 week from the 33 wt% hydrogel. 
However, the spironolactone showed an S-shaped release profile, exhibiting an initial burst 
release up to 20% within about 24 hours, and then showed a slowly increasing rate of release 
up to about 70% after 55 days152.  
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3.4.4 Release Profiles of Paracetamol and Ibuprofen Compared 
 
Looking at the release profiles of PCL when compared to IBU from a P-123 hydrogel with the 
presence of aC-dots, it is clear that PCL follows a very different release pattern. Analysis shows 
that the drug burst released up to approximately 39% within the first 15 minutes, reaching a 
maximum drug release of 70% after two hours. The rate of release is significantly faster in the 
release profile of PCL when compared to that of IBU, but both reach a similar maximum release 
percentage. The fast release of PCL should be attributed to its hydrophilic nature that allows its 
dispersion directly into the aqueous medium, as opposed to IBU that resides to the micellar 
interior.  
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Fig 3.14. In vitro release profiles of PCL and IBU in P-123 hydrogel with the presence of aC-dots against 
a phosphate buffer solution (pH 7.4). The triangles represent the hydrogel with PCL, and the squares 
represent the hydrogel with ibuprofen. 
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4. Conclusion 
Currently, the amount medicines involving nanotechnology is climbing, set to spread 
exponentially8. More specifically, with the vast potential of carbogenic nanoparticles in the field 
of medicine becoming such a significant concept of focus for so many scientists, the 
pharmaceutical industry is beginning to change. The C-dots that were synthesised in this project 
via the pyrolysis at 300°C of ethanolamine and citric acid monohydrate exhibited fantastic 
fluorescence properties upon various excitation wavelengths, with the highest emission 
intensities occurring upon excitation with UV light at wavelength 350 nm. The fluorescence 
emission intensities of the C-dots were significantly reduced upon functionalisation with 
JEFFAMINES® D-230 and D-400, with intensity decreasing along with increasing polymer size. 
This could be attributed to the large polymer increasing the total size of the particles, reducing 
the ratio of fluorescent carbon cores that are present.  The gel phase transition temperatures 
indicate that the addition of C-dots does not compromise the highly desirable injectable nature 
of the Pluronic® gel, since a sol-gel temperature was observed below the body temperature in 
all cases.   
At the same time, the fluorescence spectra indicate a clear increase in λex dependence for the 
C-dots functionalised with JEFFAMINES® in comparison to without. This characteristic shows 
promise in improved biological imaging, due to the improved penetration that Infra-red 
radiation has through living tissue.  
The in vitro drug release profiles of IBU in 32.5 wt% Pluronic® P-123 hydrogels with and without 
various types of C-dots showed that the drug release was enhanced with the presence of all 
types of C-dots. The release profiles that were most significantly enhanced could be seen for 
the 32.5% wt p-123 with JD-230 and JD-400 C-dots. Both reached a maximum drug release of 
above 95%, over a very long period of time (about 2 weeks) when dialysed at room temperature 
against a phosphate buffer solution (pH 7.4). Overall, the IBU drug release profile of the P-123 
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hydrogel with JD-230 showed the most enhanced drug release with a controlled and sustained 
release up to a maximum release of over 95%. The release profiles indicate an increase in 
maximum drug release with the presence of C-dots, showing the possibility of released of close 
packing constrains, allowing the drug to diffuse out of the gel more efficiently. In addition, the 
gels with C-dots have the potential to facilitate the diffusion of the drug by creating efficient 
channels.   
Future work to be done on carbogenic nanoparticles and their biomedical applications include 
deeper investigation into the drastically contrasting release profiles of ibuprofen and PCL when 
loaded into thermo-reversible Pluronic® gels with aC-dots. The release profiles of many different 
types of therapeutic drugs must be taken into experimentation to further understand the 
increasing potential of C-dots.  
To that end, the present work contributes significant evidence that C-dots are promising 
materials for the development of novel theragnostics, allowing simultaneous monitoring of the 
cells, while offering an additional level of drug release control. 
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